Hematologic Toxicity Observation of the Docetaxel+ Cisplatin+ Fluorouracil (TPF)Medical Protocol (OTOHTPF)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01268878|
Recruitment Status : Completed
First Posted : December 31, 2010
Last Update Posted : January 3, 2014
|Condition or disease|
|Squamous Cell Head and Neck Carcinoma|
In this study we will describe
- habits of medical staff in prescription of growth factors or antibiotic prophylaxis
- ratio of patients treated by growth factors in primary or secondary prophylaxis
- ratio of patients treated in primary prophylaxis who present a febrile neutropenia
- ratio of patients who need to be hospitalized and the duration of those hospitalizations.
- causes of lateness, of decreasing, and of stop of chemotherapy
- antibiotic and growth factors prophylaxis tolerance .
|Study Type :||Observational|
|Actual Enrollment :||130 participants|
|Official Title:||Hematologic Toxicity Observation of the TPF Medical Protocol. Description of the Impact of Febrile Neutropenia in Patients Who Receive the Chemotherapy of the TPF Medical Protocol in Head and Neck Cell Carcinoma|
|Study Start Date :||June 2010|
|Actual Primary Completion Date :||November 2011|
|Actual Study Completion Date :||November 2011|
- biologic blood counts [ Time Frame: blood test before every chemotherapy up to 4 months ]evaluation of medical status evaluation of hematologic toxicity description of clinic toxicity: fever, sepsis..
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01268878
|Principal Investigator:||ROLLAND Frederic, MD||GORTEC|